Nijmegen/Utrecht, the Netherlands – InteRNA Technologies B.V., a biopharma company engaged in the development of microRNA (miRNA)-based therapeutics for oncology, announces today the appointment of three directors to its management team. Hester Kramer, Laurens van Pinxteren, and Sijme Zeilemaker are joining the company to support its mission from 2016 onwards.
Following the final extension of the Series A financing round in October 2015, InteRNA has now added critical positions to its Management Team on preclinical, CMC, regulatory affairs and business development, to achieve the important corporate and product development steps it faces in the years to come.
Hester Kramer has joined the company as Director PK/PD. She is a pharmacokineticist and toxicologist with special focus on DMPK and (pre-)clinical PK/PD. She has over 12 years of experience in preclinical and clinical departments of Merck & Co. (MSD), and recently served as Director PK/PD at ProQR Therapeutics. She holds a PhD degree in toxicology from Utrecht University.
Laurens van Pinxteren joins InteRNA as Senior Director CMC & Regulatory Affairs. He has a focus on product development, manufacturing and tech transfer with strong regulatory interactions. Laurens was Director Manufacturing & Supply at ProFibrix from 2010 to 2015, involved in the development of Raplixa and subsequent market approvals in the EU and USA, and has over 8 years of experience as program manager at Xendo and OctoPlus. He holds a PhD degree from University of Edinburgh and an MBA from Rotterdam School of Management.
Sijme Zeilemaker has joined the company as Director Business Development. He is focused on bringing scientific ideas together with business and funding opportunities in biotech. Sijme worked at to-BBB from 2011 to 2015, during which he was responsible for partnering with pharma/biotech and able to attract over €7.5 million of non-dilutive funding. He holds a Masters degree in biomedical sciences from Leiden University.
“I am proud that we have been able to attract key people in this exciting time for InteRNA. As a team, we are now in the position to move our pipeline into the next stage of development and build a company that can bring novel treatment options forward to patients with cancer,” says Roel Schaapveld, CEO of InteRNA Technologies.
About InteRNA Technologies B.V.
InteRNA Technologies develops cancer therapeutics based on a broadly applicable proprietary technology platform for the rapid identification and validation of therapeutic miRNAs. At present, InteRNA has established in vivo proof of concept for multiple pipeline candidates. The Company is pursuing a proactive partnership strategy to acquire appropriate delivery technologies for its products and expects to engage in corporate partnerships to progress several of its products into clinical development. InteRNA Technologies was incorporated by Aglaia Oncology Fund I as a spin-off from the Hubrecht Institute, Utrecht, the Netherlands.
Roel Schaapveld, PhD, MBA Sijme Zeilemaker, MSc
Chief Executive Officer Director Business Development
Phone: +31 30 2532386 Phone: +31 6 30415770
Email: email@example.com Email: firstname.lastname@example.org
InteRNA Technologies B.V.